Every material Form 8-K Arrowhead Pharmaceuticals filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Chairman Douglass Given tendered his retirement from the Arrowhead Pharmaceuticals board, effective December 31, 2024, after serving 14 years. The company expects Sarepta Therapeutics CEO Douglas S. Ingram to join the board in the first quarter of 2025, at the closing of their license and collaboration agreement dated November 25, 2024.
Douglass Given tendered his retirement on December 11, 2024, effective December 31, 2024
Given served 14 years on the board and was serving as Chairman and a member of the Science Committee
Douglas S. Ingram, President and CEO of Sarepta Therapeutics, expected to join the board in Q1 2025, concurrent with the Sarepta agreement closing
Arrowhead Pharmaceuticals reported a fiscal 2024 net loss attributable to the company of $599.5 million, or $5.00 per diluted share, for the year ended September 30, 2024, compared with a loss of $205.3 million, or $1.92 per share, a year earlier. Revenue fell to $3.6 million from $240.7 million, while research and development expense rose to $505.9 million from $353.2 million. The company said its recent Sarepta licensing deal and Sixth Street credit facility, both announced in the filing period, extend its cash runway into 2028.
Revenue was $3.6 million in fiscal 2024 versus $240.7 million in fiscal 2023.
Diluted net loss per share was $5.00 versus $1.92 a year earlier.
Research and development expense was $505.9 million versus $353.2 million.
Sarepta agreement provides $825 million upon closing, including a $325 million equity investment; Sixth Street facility is $500 million, with $400 million funded at close.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Arrowhead Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →